SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…
Treatment with LB-102 resulted in a positive shift in disease severity as measured by mean change from baseline in Clinical…
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit…
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company…
Integration of Arabic opens opportunities in the Middle East and supports Company’s strategic global expansion goals Drug Screening Reader -…
Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash…
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025New York, New York--(Newsfile Corp.…
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceedThis news…
LOS ANGELES--(BUSINESS WIRE)--#biohacking--Next Health, the world’s most advanced and comprehensive brand of health optimization and longevity centers, has teamed up…
PROVIDENCE, R.I., March 31, 2025 /PRNewswire/ -- The Rhode Island Life Science Hub and Brown University selected Portal Innovations (Portal)…